Absci (ABSI) stock

Protein therapeutics , market cap $1.6B

Protein therapeutics

Worth $1.6B

$9.97

-7.69%

As of Tuesday's close · Live for Pro members at the open

Why is ABSI down?

Down 7.7% today, more than its biotech peers' 1.4%; no story names it yet.

Down 18% since Oct 29

Down 18% from Oct 29 to Nov 10.

Absci fell 18% from Oct 29 to Nov 10. 12 points of it came on Nov 2.

Sources: Price history, Nov 10, 2026

Tell me next time ABSI moves

Free account, no card. An optional alert when ABSI moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →How the business stands, the timeline, and its peers, for Pro members.

Why ABSI still beats the market over three years

Up 750% over the three years to Nov 9 while the S&P 500 rose 80%; down 18% since Oct 29.

1 reason, from its filings, with the timeline, for Pro members.

Quality Score

Below Average

In its industry

#117of 281

Biotech

Checks firing

3of 14

Choppy

From 52-week high

-20.5%

under its best in a year

ABSI's Quality Score fell 3 points on Tue, Nov 10, to 1. Its price fell below its average of the last 8 days (3 chart checks stopped).

Follow ABSI's trial news. Pro members can get an alert when Absci files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ABSI files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026…”Trial data · SEC filing · Aug 11

Cash$201M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into the second half of 2028”

Key facts on ABSI

Key facts on ABSI
Holding it back	Moves 10.5% a day with no profit behind it
Latest filing	10-Q, Aug 11 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind ABSI's 1, free with an account →5 more reasons behind ABSI's 1, for Pro members.

ABSI in the news

TodayNo story names it yet.

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

Cash$201M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into the second half of 2028”

ABSI catalysts

Coming up

After its last 4 reports it closed -5.4% on average, higher 2 of 4 times.

5 past catalysts since 2022, with sizes and sources, for Pro members.

What's next for ABSI, and how long its cash lasts

Next step the company has named

2H 2026“Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026 and full proof-of-concept data in early 2027.”Trial data · SEC filing · Aug 11

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic AlopeciaPhase 1/2 · Recruiting · 227 people · main data estimated Jul 2028 · NCT07317544

For Pro members: 3 more milestones and 32 filings.

Cash runway Jun 30 balance sheet

About 7 quarters

$201M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the second half of 2028” (8-K, Aug 11).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Director Mary T Szela bought 12,900 shares on Jun 30. 5 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Sean McClain buys or sells

For Pro members: every trade, and Sean McClain’s 17 filings and quotes.

Get an alert when ABSI files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ABSI scores 1

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Persistence, and News.

What every line is worth, and the reason behind it, on ABSI and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How ABSI ranks in Biotech

ABSI is #117 of 281 by Quality Score.

How ABSI ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	ABCLAbCellera Biologics		Open for its score
	ABEOAbeona Therapeutics		Open for its score
	ABUSArbutus Biopharma		Open for its score
	ABVXAbivax SA		Open for its score
117	ABSIAbsci	3/14	1

When does ABSI report earnings, and what happens after?

Reports Thu Nov 12, before the open (in 2 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ABSI reported on Aug 11, 2026

The quarter

The figures are not read from the release yet.

“This increase was primarily driven by advancement of Absci's internal programs, including direct costs associated with external preclinical and clinical development of ABS-201, offset by a decrease in personnel-related costs.”

The filing on EDGAR

Where the sales came from

ABSI's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“This increase was primarily due to stock-based compensation and other administrative costs.”

From its results filing (SEC filing · Aug 11)

2 more sentences, for Pro members.

The numbers

Market value: $1.6B; today
Sales: $1.6M; down 62.3% on the year
Free cash flow: -$109M; last 12 months

Its share count grew 15% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ABSI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-3.0%+2.6%+1.0%

Mar 24May 7Aug 11

Reported	When	Gap	Reaction	5 days
Aug 11, 2026After close	After close	-4.1%	+1.0%	-6.0%
May 7, 2026After close	After close	-12.3%	+2.6%	-3.6%
Mar 24, 2026After close	After close	-3.6%	-3.0%	-0.3%

ABSI closed higher after 2 of its last 4 reports.

All 4 reports, and ABSI's Quality Score going into each

Everyone reporting earnings this week

ABSI sales and profit by year

Sales and profit by year

Sales grew in two of the last five years, to $2.8M in 2025. It lost money in each of the six years.

ABSI has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ABSI, and all 14 on every stock.Get in free →

ABSI RSI today: 49.9, above its 50-day and 200-day averages

Not scored

RSI 49.9, MACD below signal, above both averages. Not scored.13 readings

The deep dive on ABSI

What it does and how it makes money2 findingsAn operating loss of $120M in fiscal 2025, on $2.80M of sales.Annual report, filed Mar 24, 2026
Where it stands2 findingsFor Pro members2 findings on where ABSI stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ABSI, for Pro members

5 more findings on ABSI, each with its source, for Pro members.

ABSI share count over time

23% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of ABSI outstanding, as filed
Shares outstanding	As of
171.6M	Jul 31, 2026
155.9M	Apr 30, 2026
153M	Mar 6, 2026
150.4M	Oct 31, 2025

Offerings, shelves, and splits of ABSI, from its filings
From its filings	Filed
Priced a sale of shares	Jun 24, 2026
Set up an at-the-market program for up to $100M of shares, about 6% of its market value	Aug 22, 2025
Registered shares for a later sale (S-3)	Aug 12, 2025
Raised $50M in a sale of shares, about 3% of its market value	Jul 25, 2025

ABSI insider trades

One insider bought $149K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyMary T. Szela$149KDirectorat $11.54 on Jun 30, filed Jul 6

BuyMary T. SzelaDirector$149Kat $11.54 on Jun 30, filed Jul 6

ABSI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Sean McClainChief Executive Officer · 1 trade
Zachariah JonassonCFO / CBO · 1 trade
Andreas BuschChief Innovation Officer · 1 trade
Shelby J. WalkerChief Legal Officer · no trades on file
Todd BedrickSVP, CAO · no trades on file
Menelas N. PangalosDirector · 2 trades
Mary T. SzelaDirector · 1 trade
Frans Van HoutenDirector · 1 trade

3 more officers and directors file at ABSI.

See insider trades by person

Which ETFs hold ABSI?

In ETFs: ABSI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

140 employeesVancouver, WAabsci.com

What Absci says it competes with

“We also face competition from entities that have made substantial investments in developing treatments for the therapeutic indications which our internal programs and partnered programs target.”

From its annual report, SEC filing · Mar 24, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ABSI and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ABSI's score around: 8 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 6Mary T. Szela bought ABSI$149K at $11.54, filed Jul 6

Alerts are optional.

See ABSI's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ABSI's Quality Score is 1 (Below Average), #117 of 281 in Biotech. Insiders bought $149K in the last 6 months (Form 4).

What does ABSI's Quality Score say?

ABSI scores 1 today, which Breakaway calls Below Average. It is #117 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 18% from Oct 29 to Nov 10. Cash lasts about 7 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ABSI's Quality Score?

ABSI scores 1 today, which Breakaway calls Below Average (0 to 5). That is #117 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABSI's 1.

Are insiders buying ABSI?

One insider bought $149K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Mary T. Szela, Director, who bought $149K on Jun 30.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.